EBERS MEDICAL TECHNOLOGY SL

Their core work

EBERS Medical Technology is a Zaragoza-based SME that designs and manufactures biomedical devices for organ preservation and tissue engineering. Their flagship product line centers on normothermic perfusion systems — machines that keep donated kidneys and livers alive and functional outside the body, enabling viability assessment before transplantation. They also contribute bioreactor and biomechanics expertise to cardiac tissue engineering and 3D bioprinting projects, bridging the gap between laboratory-scale tissue constructs and clinical-grade regenerative medicine products.

What they specialise in

How they've shifted over time

EBERS began with a tight focus on organ transplant logistics — specifically building perfusion devices that keep donor organs viable during transport (NORMOPERF, 2016–2023). From 2020 onward, they expanded into cardiac tissue engineering and 3D bioprinting through the BRAV3 project, adding computational modelling, hiPSC cell biology, and biomaterials to their portfolio. This trajectory shows a company moving from preservation of existing organs toward engineering new tissue constructs — a logical but ambitious expansion of their biomedical hardware capabilities.

EBERS is expanding from organ preservation hardware into the broader regenerative medicine space, combining their device engineering roots with computational modelling and tissue engineering — positioning them as a hardware partner for next-generation bioprinting consortia.

How they like to work

EBERS primarily leads its own projects — coordinating 2 out of 3 H2020 grants, both through the SME Instrument (Phase 1 and Phase 2), which signals strong commercial ambition and the ability to drive a project from feasibility through to market. In BRAV3, they joined a larger RIA consortium as a participant, contributing specialized device and biomechanics expertise to a broader team. With 17 partners across 7 countries from just 3 projects, they are comfortable in international consortia and bring practical engineering capabilities rather than just research.

EBERS has collaborated with 17 distinct partners across 7 countries, primarily through the large BRAV3 consortium. Their network spans multiple European countries, reflecting the international nature of the biomedical device and tissue engineering community.

What sets them apart

EBERS occupies a rare niche as an SME that builds actual biomedical hardware — perfusion machines, bioreactors — rather than doing purely academic research. Their successful progression from SME Instrument Phase 1 to Phase 2 (a 50x funding increase) demonstrates validated commercial potential and execution capability. For consortium builders, they offer something hard to find: a small, agile company that can design, prototype, and manufacture specialized biomedical devices, bridging the gap between laboratory research and clinical products.

Highlights from their portfolio

• NORMOPERF
  Completed the full SME Instrument journey (Phase 1 → Phase 2, EUR 2.6M), validating their organ perfusion device concept from feasibility to near-market — one of the clearest commercialization trajectories in the dataset.
• BRAV3
  A major RIA project (EUR 559K to EBERS) combining cardiac 3D bioprinting, hiPSC technology, and computational modelling — represents their strategic expansion from organ preservation into regenerative medicine.